The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Astaf'eva L.I.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Kadashev B.A.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Sidnevа Yu.G.

Clinical and Research Institute of Emergency Children’s Surgery and Traumatology, Moscow Health Department, Moscow, Russia

Chernov I.V.

Sechenov First Moscow State Medical University, Moscow, Russia

Kalinin P.L.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Pituitary microadenomas — current diagnostic and treatment methods

Authors:

Astaf'eva L.I., Kadashev B.A., Sidnevа Yu.G., Chernov I.V., Kalinin P.L.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2020;84(2): 110‑120

Views: 117756

Downloaded: 1779


To cite this article:

Astaf'eva LI, Kadashev BA, Sidnevа YuG, Chernov IV, Kalinin PL. Pituitary microadenomas — current diagnostic and treatment methods. Burdenko's Journal of Neurosurgery. 2020;84(2):110‑120. (In Russ., In Engl.)
https://doi.org/10.17116/neiro202084021110

Recommended articles:
Functional hype­rcortisolism in mental diso­rder — asso­ciation with psychopathological mani­festations and course of the disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):130-136

Abbreviations

ACTH — adrenocorticotropic hormone

CD — Cushing's disease

EIPA — endocrine-inactive pituitary microadenoma

IGF-1 — insulin-like growth factor 1

CT — computed tomography

PMA — pituitary microadenoma

MRI — magnetic resonance imaging

PRL — prolactin

GH — growth hormone

TSH — thyroid-stimulating hormone

TSH-PMA — thyrotropinoma

T4 — thyroxine

T3 — triiodothyronine

Pituitary microadenomas (PMA) are adenomas with a diameter of less than 10 mm. Endocrine-active (somatotropinoma, corticotropinoma, prolactinoma, thyrotropinoma) and endocrine-inactive pituitary microadenomas are distinguished depending on endocrine activity. EIPA are mainly detected as “random findings”. Therefore, these tumors are commonly called pituitary incidentalomas. Currently, there are no clear indications for treatment and follow-up of these tumors. Incidentalomas also include endocrine-active PMA without clear clinical picture which are randomly diagnosed during magnetic resonance imaging (MRI).

Epidemiology

Analysis of actual prevalence of this disease is a rather difficult task due to small dimensions and asymptomatic course of various PMA [1]. Currently, according to European data, an approximate prevalence of pituitary adenomas is 1: 1000 in general population [2–4]. This value is 5 times higher than data reported 15 years ago [1].

In various studies, incidence of pituitary incidentaloma was assessed using autopsy, CT or MRI of the brain. These examinations were carried out without regard to pituitary diseases and compression syndrome. According to autopsies of patients died from various diseases without previous clinical manifestations of pituitary diseases, pituitary incidentaloma were detected in 1.4–27% of cases. Variety of data is probably determined by different number and thickness of slices during autopsy. Microincidentalomas are detected in 4–20% of adults undergoing CT for reasons not related to pituitary diseases. This value reaches 10–38% in case of MRI [5].

Incidence of these lesions is similar in men and women. Age-related differences are absent. However, there are almost no literature data on pituitary incidentalomas in children. The majority of microincidentalomas (with the exception of pituitary hyperplasia) are presumably endocrine-inactive adenomas having no clinical significance throughout the life. The optimal strategy for surveillance or treatment of patients with these tumors has not yet been determined [6].

Data on the prevalence of EIPA among incidentalomas are mainly available from small retrospective trials and autopsy data. One large sample included 3048 autopsies. There were 334 pituitary adenomas in 316 people (157 men and 159 women) who died aged 28 to 97 years (mean 73 years). Prolactinoma was diagnosed in 39.5% of cases, ACTH-releasing tumor — 13.8%, growth hormone-releasing adenoma — only 1.8%. Multiple adenomas as separate nodes were detected in 17 out of 334 cases (16 people with 2 adenomas and 1 patient with 3 adenomas). The largest tumor was usually endocrine-active (prolactinoma or corticotropinoma), the second and/or third tumor were commonly endocrine-inactive [7].

Clinical data confirm above-described distribution of tumors in population. Prolactinoma is the most common endocrine-active pituitary adenoma accounting for up to 80% of all endocrine-active pituitary adenomas [2, 8] and 40—66% of all pituitary adenomas [9, 10]. According to various sources, microadenomas account for about 36—80% of prolactinomas [3, 11, 12].

A large study of the prevalence of endocrine-active pituitary adenomas was conducted in the Liege region of Belgium in 2006. Various regions with a total population of 71,972 people were studied. Prevalence of pituitary adenomas was 1 case per 1064 people. Prolactinomas were found in 66.2% of cases while microprolactinomas accounted 80% of these neoplasms and were diagnosed in women as a rule [9].

Other endocrine-active adenomas are much less common. Thus, somatotropinomas (macro- and microadenomas) make up 8—16% of all pituitary adenomas, corticotropinomas (microadenomas as a rule) — 2—6%, thyrotropinomas — less than 1% [13].

Is there growth of microincidentalomas? This question remains unclear. According to the literature, PMA enlargement is infrequently observed (10–13% of cases) and their transition to the category of macroadenomas (exceeding 1 cm) occurs in less than 5% of cases [14]. According to meta-analysis, enlargement of only 1.7% of endocrine-inactive microincidentalomas was observed within a year. It should be noted that none of these patients developed visual impairment that would require surgical intervention [15].

A comprehensive analysis of medical records of patients with microprolactinomas who refused treatment revealed a low risk of progression to macroprolactinoma (6.5—10%). In this regard, some authors consider micro- and macroprolactinomas to be two different diseases [16].

Obviously, tumor dimension is an important predictor of any successful treatment. Surgical outcome was better in patients with different types of PMA compared with the same types of macroadenomas [16]. Diagnosis of PMA is valuable to start treatment until the stage of obvious clinical manifestations, before progression to pituitary macroadenoma accompanied by endocrine aggravation and visual complications. However, there are currently no markers of PMA with potential for growth which would be valuable for treatment or surveillance onset.

Morphological features of pituitary gland and topographic localization of microadenomas

Human pituitary gland is a complex endocrine organ localized in sella turcica. Pituitary gland consists of two lobes: anterior (adenohypophysis) and posterior (neurohypophysis) lobes. Pituitary gland of an adult weighs about 0.6 g. Transverse dimension is about 10—13 mm, anteroposterior length — 9—10 mm, vertical dimension — 5—6 mm. Morphological studies of normal pituitary gland revealed the diversity of its cellular composition (Fig. 1).

Fig. 1. Normal spatial arrangement of secretory cells in adenohypophysis depending on hormone releasing; horizontal view (diagram). Adapted from B.W. Scheithauer, E. Horvath, R.V. Lloyd, K. Kovacs. Pathology of pituitary adenoma and pituitary hyperplasia. In: Thapar K., Kovacs K., Scheithauer B.W., Lloyd R.V, eds. Diagnosis and Management of Pituitary Tumors. Totowa, NJ: Humana Press; 2001;91-154 [18]. GH — growth hormone; PRL — prolactin; ACTH — adrenocorticotropic hormone; TSH — thyroid-stimulating hormone.
So, somatotrophic cells account approximately 50% and are mainly localized in the lateral wings of pituitary gland. Lactotrophic cells (about 15—20% of pituitary cells) are also localized in the lateral wings of pituitary gland. Corticotrophic cells make up 15—20% and are concentrated in the median mucoid wedge. This wedge contains accumulations of thyrotrophic cells (5% of cells) within its upper border (at the rostral end). Gonadotrophic cells are disseminated throughout the gland and make up about 10% of pituitary cells [17, 18].

Localization of endocrine-active cells in pituitary tissue coincides with the most frequent localization of PMA of various endocrine activity. Thus, microprolactinomas are mainly localized in the posterolaterosellar parts of pituitary gland, microcorticotropinomas — in central and ventral parts of pituitary gland. These data are confirmed by MRI [19].

Clinical and endocrine features of pituitary microadenomas

Prolactin-releasing pituitary microadenomas

Prolactin-releasing pituitary microadenomas (microprolactinomas) are mainly found in young women of reproductive age, while macroprolactinomas are more common in men [20—22]. Clinical picture is manifested by hyperprolactinemia syndrome. Women have menstrual irregularities [23]. Unlike macroprolactinoma with high incidence of amenorrhea, microprolactinoma is often associated with oligomenorrhea.

Microprolactinomas are rarely detected in men. Probably, this is due to unclear clinical picture. Clinical symptoms are impaired libido, erectile dysfunction, impaired sperm quality and infertility.

Blood prolactin level usually correlates with tumor dimension. Macroprolactinomas are usually followed by prolactin level of 10,000 mU/L (500 ng/L) and even 1 million mU/L (50,000 ng/L) in case of giant tumor. On the contrary, microprolactinomas are usually associated with prolactin level of 3,000—5,000 mU/L (150—250 ng/L). In a large-scale multiple-center study conducted in Brazil, mean prolactin level for microprolactinoma was 165.6 ng/L (͌3477 mU/L), for macroprolactinoma — 1244.9 ng/L (͌26000 mU/L) [24].

Dopamine agonist therapy is preferred for prolactinoma and ensures normalization of prolactin level and decrease of tumor dimension in most patients. Cabergoline is the most effective drug with prolonged action. This medicine is highly effective in the treatment of prolactin-releasing pituitary micro- and macroadenomas.

According to current international and national guidelines, decrease or cancellation of dose is recommended no earlier than after 2 years of continuous treatment. Essential requirements are long-term normalization of prolactin level and significant reduction of tumor or its absence according to MRI data. Complete recovery is highly likely in patients with microprolactinoma undergoing dopamine agonist therapy for at least two years [10].

Some patients with microprolactinoma and asymptomatic course of disease do not require medication due to low probability of tumor growth. This approach is advisable in premenopausal patients with ensured preservation of menstrual cycle and in peri- and postmenopausal women when elevated prolactin levels do not contribute to the development of hypogonadism [10, 25].

Surgical treatment of microprolactioma is indicated in patients with resistance to dopamine agonists or intolerance to these drugs. Moreover, this approach may also be an alternative to medication. Transsphenoid surgery is an effective treatment for microprolactinoma and small endosellar tumors. Clinical outcomes and economic costs of simultaneous resection of these tumors are comparable to those with medication over a 10-year period. Various trials included a total of 627 patients. According to these data, effectiveness of surgical treatment of microprolactinoma determined by early postoperative normalization of prolactin reaches 83.2% with a recurrence rate of 10.3%. In general, these values ensure successful long-term outcomes in 75% of cases if surgery is performed by experienced “pituitary” surgeons [26—29].

In our opinion, R. Salvatori correctly noted that surgical treatment should be discussed in a patient (especially young age) with microprolactinoma considering the modern achievements of endoscopic technologies. Indeed, an effectiveness of surgical and drug treatment is approximately equal while timing of achievement of the desired result differs fundamentally (years for drug therapy and immediate result for surgical treatment) [26, 30].

Differential diagnosis of PMA followed by hyperprolactinemia includes endocrine-inactive PMA and benign hyperprolactinemia, in particular, primary hypothyroidism, macroprolactinemia syndrome (prevalence of complexes of prolactine molecules with immunoglobulin G characterized by high molecular weight and low activity), drug-induced hyperprolactinemia. The drugs affecting dopamine system include anticonvulsants, antidepressants (amitriptyline, etc.), H2-histamine receptor blockers (cimetidine, etc.), dopamine synthesis inhibitors (methyldopa, etc.), calcium channel blockers (verapamil), dopamine blockers (metoclopramide etc.), acetylcholine antagonists, various antipsychotics, opiates and cocaine drugs, as well as combined oral contraceptives with high level of estrogen.

Growth hormone-releasing PMA

Acromegaly is a severe neuroendocrine disease caused by growth hormone-releasing pituitary adenoma. Acromegaly is associated with chronic hypersecretion of growth hormone and insulin-like growth factor 1 (IGF-1). Acromegaly is a rare disease. The prevalence of acromegaly is 2.8—13.7 cases per 100,000, incidence is 0.2–1.1 cases per 100,000 [4, 31, 32].

Diagnostic criteria for acromegaly have dramatically changed over the years and the number of patients with this disease has increased significantly. This is due to a better awareness of physicians about this disease and improved laboratory diagnosis and MRI scanners. So, L.M. Davidoff reported 100 surgical cases of acromegaly in 1926. X-ray data of enlarged sella turcica were observed in 93% of patients, large pituitary tumors followed by compression of chiasm and optic nerves and visual disturbances – in 62% [33]. These indicators have significantly changed in subsequent years. Incidence of visual impairment has decreased to 27% for the period from 1951 to 1975 as a result of better awareness of this disease. Availability of growth hormone level analysis and CT has resulted decrease of the incidence of visual impairment to 15.4% in 1976—1996. Analysis of IGF-1 was used for diagnosis of acromegaly at the end of the 70s of the last century, MRI – since the 90s. These measures ensured early diagnosis in patients with mild manifestations and small tumors, so that prevalence of large adenomas associated with visual impairment has decreased to 5.2% in 1982—2006 [34].

Nevertheless, PMAs are much less common in patients with acromegaly in contrast to prevalence of PMA among microprolactinomas. According to the trial conducted in the Liège city (Belgium), pituitary macroadenomas were identified in 71.6% out of 3173 patients with acromegaly. PMA were significantly more common in older patients, while macroadenomas with invasion into cavernous sinuses predominated in young people [35].

According to the literature, patients with growth hormone-releasing PMA have less pronounced clinical manifestations of acromegaly than patients with macroadenoma. A special group of patients with "micromegaly" and mild symptoms (or their absence) has been recently identified. Moderate hypersecretion of IGF-1 and normal level of growth hormone are typical for these patients. Patients with micromegaly were significantly older (mean age 52±2 years) while mean age of patients with high levels of growth hormone was 44±1.4 years. Moreover, PMAs were significantly more common compared with patients with high levels of growth hormone. P. Petrossians et al. revealed PMAs in 48% of cases among 48 patients with micromegaly. However, PMAs were diagnosed only in 12% among 108 patients with high levels of growth hormone. In patients with PMAs, normal level of growth hormone was detected in 64% of cases, high level of growth hormone — only in 36% of cases [34].

Thus, growth hormone-releasing PMAs are more often detected in older people, accompanied by milder clinical manifestations compared to macroadenomas, normal levels of growth hormone and moderate elevation of IGF-1.

The goals of treatment of growth hormone-releasing PMAs are elimination of tumor, normalization of the levels of growth hormone and IGF-1, regression of symptoms, management of complications of acromegaly and reducing the risk of mortality from comorbidities (cardiovascular and respiratory dysfunction, diabetes mellitus, etc.).

Pituitary adenomectomy is preferred for the management of acromegaly. In specialized “pituitary” centers, complete resection of PMA is performed in 80–95% of patients with acromegaly [36].

Medication is used in case of contraindications for surgery, partial resection of pituitary tumor. Preferable drugs are prolonged analogues of somatostatin, which are more effective for PMA compared with macroadenomas. Adjuvant therapy after partial resection of tumor also includes dopamine agonists. These drugs may be prescribed for moderate manifestations of acromegaly and/or more than 2 norms of IGF-1. These signs usually characterize growth hormone-releasing PMAs [37].

Radiotherapy for acromegaly is used only if surgical approach and medication are ineffective.

ACTH-releasing pituitary microadenoma

In 85% of cases, ACTH-releasing tumors are represented by microadenomas with a diameter of 1—2 mm localized in the central part of adenohypophysis [19].

Pituitary hypersecretion of ACTH results chronic hypersecretion of cortisol in adrenal cortex and manifestation of Cushing's disease. The last one is followed by dysplastic obesity, hypertension, impaired fertility, carbohydrate metabolism, osteoporosis, cognitive impairment and other disorders [38, 39].

According to the guidelines, at least two tests are necessary for diagnosis of hypercorticism: saliva cortisol at 23:00 and serum cortisol in the morning after previous oral intake of dexamethasone 1 mg at 23:00 (suppression test). Additional examinations are indicated if data of these tests are controversial (cortisol urine test, serum cortisol in the evening). Analysis of ACTH in the morning is necessary if two tests confirm hypercorticism. Contrast-enhanced MRI of the brain (1.5—3.0 T MRI scanner) is required in case of cortisol level ≥10 pg/ml [40]. Imaging of microcorticotropinoma was an extremely difficult task until 1980 when MRI became the main method for diagnosis of these tumors. MRI was able to detect tumors up to 5 mm in diameter [41, 42].

Undoubtedly, endoscopic endonasal transsphenoid adenomectomy is the main and most effective method of treatment of PMA in patients with Cushing's disease. This procedure ensures high remission rate (65—90%) after preoperative MRI [43, 44].

However, Cushing's disease may be caused by very small PMA which cannot be detected even on the most sensitive MRI scanners. These are the so-called MRI negative PMAs. These tumors are characterized by significantly lower remission rates [45]. High-resolution MRI with a slice width of 1 mm may be valuable to detect PMA prior to surgery. This method makes it possible to diagnose PMA even if visualization is absent during conventional MRI [45, 46]. Another option is contrast-enhanced MRI [46].

These cases comprise an extremely difficult problem for pituitary surgeons considering the absence of a clear surgical target. Diagnostic bilateral blood sampling from inferior petrous sinuses is usually used to determine ACTH gradient including stimulation with corticoliberin in patients with suspected Cushing's disease and no MRI data on pituitary adenoma [39]. However, this method is not absolutely reliable for pituitary adenomas [45]. Some ACTH-releasing PMAs may be outside the sella turcica including mucosa of sphenoid sinus, cavernous sinus or neurohypophysis. Surgeons should analyze advisability of total or partial resection of pituitary gland if adenoma is not found after a thorough intraoperative examination of adenohypophysis. Remission occurs in 60—75% of patients after total or partial hypophysectomy. However, almost all of these patients develop postoperative panhypopituitarism.

R.F. Dallapiazza offers hemihypophysectomy (on the side of high ACTH gradient determined by selective blood sampling from inferior petrous sinuses) or subtotal hypophysectomy. Thus, 30% of the gland is resected from the either side and 20% from the lower side. Only 20—30% attached to pituitary stalk is preserved. In these cases, incidence of postoperative pituitary insufficiency is only 15—20%. The criterion of hypercorticism remission after resection of pituitary micro- and macroadenomas is a decrease of cortisol level in the morning <50 nmol/L in early postoperative period.

Recurrence rate after resection of microcorticotropinoma is 5—10% after 5 years and 10—20% after 10 years [45, 46]. Redo neurosurgical treatment is also preferred for recurrent Cushing's disease. Medication and radiotherapy for microcorticotropinoma are mainly used in case of contraindications to surgery or absence of remission of hypercorticism after neurosurgical treatment.

TSH-secreting microadenoma

The criterion of TSH-secreting pituitary adenoma (thyrotropinoma) is visualization of tumor at normal or elevated levels of TSH, elevated concentrations of thyroxine and triiodothyronine. TSH hypersecretion is followed by advanced stimulation of thyroid function and clinical picture of “central” hyperthyroidism.

TSH-PMA is a rare pituitary tumor. These neoplasms account for 0.5% –2% of all pituitary tumors, overall prevalence is 1—2 cases per 1 million [47]. According to the recent data of the Swedish registry of pituitary tumors, there is an increase of the incidence of TSH-PMA for the period from 1990 to 2009. In 2010, this value was 2.8 per 1 million [12].

Previously, TSH-PMA were considered casuistic tumors and usually diagnosed at the stage of large invasive pituitary macroadenomas. However, supersensitive endocrine laboratory methods and high-resolution neuroimaging, as well as higher awareness of endocrinologists and general practitioners ensured earlier identifying TSH-PMA of small dimensions. Thus, PMA are recorded more often in the last decade.

TSH-PMA are manifested by hyperthyroidism (from asymptomatic and mild symptoms to severe thyrotoxicosis) [48, 49]. Severity of PMA-associated hyperthyroidism is often much less than expected by the level of thyroid hormones. Cardiac toxicosis with atrial fibrillation and/or heart failure are very rare [50].

By the moment of tumor diagnosis, these patients may have a long history of incorrectly diagnosed Graves’ disease (diffuse toxic goiter). Symptoms of this disease are also associated with hyperthyroidism, but they develop due to the effect of antibodies on TSH-receptors rather TSH per se [51]. Rare diagnosis of these tumors and insufficient awareness of physicians on clinical features and diagnosis of central hyperthyroidism may be followed by overdiagnosis of diffuse toxic goiter or other thyroid diseases accompanied by hyperthyroidism. Moreover, unjustified thyroid surgery (for example, thyroidectomy and/or therapy with radioactive iodine in 30% of patients) is also possible [50, 52]. In this case, treatment is followed by decrease of the level of circulating thyroid hormones and tumor growth activation. The mechanism is similar to the development of Nelson's syndrome after bilateral adrenalectomy in patients with Cushing's disease.

Some patients can appeal for a medical care due to symptoms of acromegaly or menstrual irregularities in women. This is caused by concomitant production of prolactin (10% of cases) or growth hormone (16% of cases) by TSH-releasing tumors [50].

Adenomectomy is preferred for TSH-PMA. The goal of surgical treatment of TSH-releasing micro- and macroadenomas is their total resection and normalization of thyroid hormones [53].

Remission rate in patients with TSH-releasing PMA is 80—100% compared with 44—81% in patients with macroadenomas [54]. Undetectable serum TSH may be a good indicator of total resection. Importantly, undetectable level of TSH is accepted as concentration below functional sensitivity of diagnostic method (<0.01 mU/l).

Therapy with somatostatin analogues reduces TSH level, normalizes levels of thyroxine and triiodothyronine and restores euthyroidism in 90% of cases although adenomectomy is preferable approach. Analogues of somatostatin are effective in achieving euthyroidism in patients with TSH-PMA and mixed TSH- and growth hormone-releasing tumors and may be an alternative to surgical treatment [47].

Early diagnosis of these tumors and differential diagnosis with other diseases accompanied by hyperthyroidism are extremely important. Currently, diagnosis of TSH-PMA at the stage of microadenoma accompanied by hyperthyroidism without compression symptoms (visual and neurological disorders) is being gradually improved.

Endocrine-inactive pituitary microadenoma

Endocrine-inactive pituitary microadenoma are not associated with clinical manifestations and usually detected as incidentalomae. Perhaps, endocrine-inactive pituitary microadenoma is expectable approximately in every fifth human. Management of these patients is of great interest [1].

Currently, availability of MRI scanners and various examinations has significantly increased the number of people who are referred by various specialists without regard to endocrine disorders (headache, dizziness, etc.) or go on their own for “check-up” diagnosis (a set of preventive medical examinations for analysis of person’s health) including diagnostic MRI.

Interpretation of MRI data may be ambiguous. Not all suspicious neoplasms within sella turcica are pituitary adenomas. Microadenoma may be suspected in case of intrasellar small neoplasm with a diameter of less than 10 mm. The tumor is localized in anterior lobe of pituitary gland and displaces pituitary stalk posteriorly. If endocrine disorders are absent, differential diagnosis should include Rathke’s cleft cyst, small intrasellar craniopharyngioma, etc. [15, 55].

It is also necessary to differentiate pituitary adenoma and pituitary hyperplasia. The last one may be observed in physiological conditions (pregnancy, adolescence), inflammation of pituitary gland and intracranial hypotension syndrome (confirmed by orthostatic headache and MRI data) [56]. In recent series, pituitary adenomas accounted 71% of initially diagnosed pituitary incidentalomas [57].

According to national and international guidelines, it is necessary to exclude endocrine activity of the tumor in a patient with microincidentaloma (namely, hyperprolactinemia, acromegaly, hypercorticism) [5, 58]. Therefore, analysis of serum prolactin and IGF-1, saliva cortisol at 23:00 and suppression test are required. Some authors propose an additional analysis of TSH and T4 to exclude rare central hyperthyroidism. Surveillance may be advisable if endocrine activity of tumor is absent.

Can endocrine-inactive pituitary microadenoma lead to hypopituitarism? There is no clear answer this question in the latest clinical guidelines of the European Society of Endocrinology. Examination for hypopituitarism is recommended for microincidentalomas over 6—9 mm. Routine screening for hypopituitarism is not required for smaller PMA since its probability is very low. Follow-up endocrine testing is also not recommended for endocrine-inactive pituitary microadenoma because clinical picture of these tumors remains the same. None patient with endocrine-inactive pituitary microadenoma had pituitary disorders. However, these trials are extremely few [5].

A follow-up MRI of pituitary gland is recommended in 1 year after detection of endocrine-inactive pituitary microadenoma. If dimensions of microincidentaloma do not change, “wait and see” approach is advisable (MRI after 1—2 years for 3 years with subsequent increase of interval between studies) (Fig. 2).

Fig. 2. Treatment algorithm for pituitary microadenoma.
A special protocol of MRI for analysis of dimensions of pituitary tumor is desirable (slice width of 1—2 mm with or without contrast enhancement).

Neuroophthalmological examination (visual fields and visual acuity) is necessary in patients with PMA if the tumor is being enlarged and localized near to optic nerve chiasm. This survey is not indicated in patients without symptoms, tumor enlargement and compression of optic nerve chiasm.

Medication for pituitary incidentaloma has not been systematically studied. Some parallels with the effects of drug therapy on hormone-inactive macroadenomas are possible. According to the literature, effectiveness of therapy with dopamine agonists for endocrine-inactive macroadenomas significantly varies. Administration of cabergoline or bromocriptine in patients with residual postoperative tumor tissue is followed by reducing tumor dimensions 8—45% of cases, degree of reduction varied from 10 to 62% (3—14 mm). Administration of somatostatin analogues ensured decrease of tumor dimensions in 5—25% of cases, stabilization — in 83% of cases of endocrine-inactive adenomas. Nevertheless, current data are insufficient for routine therapy of microincidentaloma [5].

Considering high prevalence of endocrine-inactive pituitary microadenoma and need for follow-up examination of these patients, it should be remembered that the cost of this survey is an important issue. American researchers B.R. Randall et al. analyzed the cost of examination in a specialized pituitary center including 2-fold contrast-enhanced MRI, serum hormones, initial and repeated consultations of neurosurgeon, endocrinologist and radiologist. The cost ranged from 6061 to 6215$ per a patient with microincidentaloma. Therefore, high costs in healthcare system are expected [59].

Conclusion

Currently, availability of high-resolution magnetic resonance imaging scanners is followed by significantly increased incidence of detection of pituitary microadenomas as “random findings”. A differentiated approach to their treatment is used depending on endocrine activity. Surgical or drug treatment is required for endocrine-active microadenomas.

However, endocrine-inactive microadenomas are more common. These tumors do not usually require treatment considering extremely low probability of growth. Therefore, magnetic resonance imaging with gradual increase of the interval between examinations is optimal.

We reported treatment algorithm depending on endocrine activity of pituitary microadenomas. Dopamine agonist therapy is preferred for microprolactinoma. Neurosurgical treatment may be suggested as an alternative method. Neurosurgery is indicated for microadenomas accompanied by hypersecretion of growth hormone, ACTH and TSH. Follow-up with repeated MRI may be suggested for endocrine-inactive pituitary microadenomas. Surgery is indicated for tumor enlargement, visual and/or hypopituitary disorders.

Further development of neuroimaging including high-resolution MRI scanners can increase incidence of detection of pituitary microadenomas. In addition, highly sensitive examination methods and their wide availability may be valuable for identification of mild elevation of pituitary hormones in patients without any clinical symptoms.

There is a question about appropriateness of treatment of these tumors. On the one hand, diagnosis of endocrine-active microadenoma ensures timely treatment and prevention of progression of endocrine disease. On the other hand, pituitary microadenoma is not always associated with further symptoms. Therefore, there is a danger of overdiagnosis (the so-called "disease of modern technologies"). Further studies will allow us to identify the true prevalence of pituitary adenomas and those patients who require treatment, follow-up, any medical and diagnostic procedures.

Authors’ participation:

Concept and design of the study — L.A.

Collection and analysis of data — I.Ch., Yu.S.

Writing the text — L.A., I.Ch.

Editing — B.K., P.K.

The authors declare no conflicts of interest.

Commentary

The authors present a literature review devoted to such fairly common disease as pituitary microadenoma. There are no clear guidelines for the diagnosis and treatment of patients with pituitary microadenoma despite numerous publications on this issue. Unfortunately, there are cases of delayed diagnosis of even endocrine-active microadenomas followed by Cushing's disease and acromegaly. Therefore, the report is extremely relevant for various specialists. Awareness of general practitioners on the clinical picture, diagnosis and course of endocrine-active pituitary microadenoma ensures early diagnosis of disease and referring patients to specialized "pituitary" centers. Early diagnosis of these diseases is associated with improved outcomes, the absence of comorbid complications of Cushing's disease and acromegaly, reduced risk of disability of these patients. Follow-up of patients with endocrine-inactive microincidentaloma may be considered relevant considering low incidence of transformation of pituitary microadenoma into macroadenoma. Compliance with the management algorithms in these patients, on the one hand, reduces cost of the treatment and, on the other hand, facilitates identifying patients who need medical or surgical treatment.

The report may be published and is recommended for reading by various specialists.

A.Yu. Grigoriyev (Moscow, Russia)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.